What is the share price of Windlas Biotech Ltd (WINDLAS) today?
The share price of WINDLAS as on 15th July 2025 is ₹924.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Windlas Biotech Ltd (WINDLAS) share?
The past returns of Windlas Biotech Ltd (WINDLAS) share are- Past 1 week: 0.11%
- Past 1 month: -2.14%
- Past 3 months: -13.57%
- Past 6 months: -7.98%
- Past 1 year: 32.79%
- Past 3 years: 326.82%
- Past 5 years: 127.07%
What are the peers or stocks similar to Windlas Biotech Ltd (WINDLAS)?
The peers or stocks similar to Windlas Biotech Ltd (WINDLAS) include:What is the dividend yield % of Windlas Biotech Ltd (WINDLAS) share?
The current dividend yield of Windlas Biotech Ltd (WINDLAS) is 0.64.What is the market cap of Windlas Biotech Ltd (WINDLAS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Windlas Biotech Ltd (WINDLAS) is ₹1909.39 Cr as of 15th July 2025.What is the 52 week high and low of Windlas Biotech Ltd (WINDLAS) share?
The 52-week high of Windlas Biotech Ltd (WINDLAS) is ₹1198.25 and the 52-week low is ₹659.What is the PE and PB ratio of Windlas Biotech Ltd (WINDLAS) stock?
The P/E (price-to-earnings) ratio of Windlas Biotech Ltd (WINDLAS) is 31.31. The P/B (price-to-book) ratio is 3.78.Which sector does Windlas Biotech Ltd (WINDLAS) belong to?
Windlas Biotech Ltd (WINDLAS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Windlas Biotech Ltd (WINDLAS) shares?
You can directly buy Windlas Biotech Ltd (WINDLAS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Windlas Biotech Ltd
WINDLAS Share Price
924.501.48% (+13.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
WINDLAS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
WINDLAS Performance & Key Metrics
WINDLAS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.31 | 3.78 | 0.64% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.43 | 6.45 | 0.81% |
WINDLAS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
WINDLAS Company Profile
The company provides pharmaceutical development services. It provides contract manufacturing services for pharmaceutical industrialists and also focuses on product development and manufacturing capabilities in generic products.
SUNPHARMA
PE Ratio
36.94
36.94
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.73
22.73
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
60.29
60.29
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
55.89
55.89
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.40
18.40
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
WINDLAS Sentiment Analysis
WINDLAS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
WINDLAS Stock Summary · May 2025
In Q4 FY25, the company demonstrated robust revenue growth of 20% year-over-year, driven by strategic initiatives in exports and product diversification, despite facing challenges such as increased depreciation costs and regulatory compliance. With current capacity utilization for oral solids at 60%-62%, plans to enhance manufacturing capabilities are underway, particularly in the growing Generic Formulations CDMO and Trade Generics segments. The injectable business, while burdened by fixed costs, is expected to improve as production ramps up and regulatory approvals are secured. A strong working capital cycle of 14 days reflects financial discipline, enabling the company to explore organic and inorganic growth opportunities while maintaining a commitment to shareholder value through dividends. Overall, management remains optimistic about future growth, particularly in export markets and the evolving trade generics landscape.
WINDLAS Stock Growth Drivers
WINDLAS Stock Growth Drivers
7Strong Financial Performance
Windlas Biotech Limited reported a robust financial performance for FY '25, achieving a revenue of
Growth in Key Business Verticals
The Generic Formulations CDMO vertical achieved a revenue of INR 555.1 crores, reflecting a 15%
WINDLAS Stock Challenges
WINDLAS Stock Challenges
4Discrepancies in Export Revenue Reporting
There are significant discrepancies in the company's reported export sales data compared to third-party agency
Financial Management Concerns
There is a noted decrease in cash and bank balances alongside increases in inventory, investments,
WINDLAS Forecast
WINDLAS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
WINDLAS
WINDLAS
Income
Balance Sheet
Cash Flow
Annual Normal View
WINDLAS Income Statement
WINDLAS Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 356.54 | 361.07 | 331.34 | 436.34 | 472.64 | 523.05 | 644.43 | 777.90 | 777.90 | |||||||||
Raw Materials | 234.55 | 188.27 | 224.35 | 270.74 | 307.56 | 340.71 | 386.59 | 493.38 | 665.77 | |||||||||
| Power & Fuel Cost | 7.29 | 7.28 | 8.04 | 11.53 | 11.01 | 12.90 | 16.15 | 21.61 | ||||||||||
| Employee Cost | 44.54 | 42.96 | 43.57 | 58.32 | 63.41 | 70.32 | 87.46 | 122.92 | ||||||||||
| Selling & Administrative Expenses | 13.80 | 18.29 | 16.25 | 15.09 | 23.55 | 30.15 | 35.89 | 33.54 | ||||||||||
| Operating & Other expenses | 12.69 | 12.72 | 2.65 | 44.67 | 7.98 | -1.23 | 26.70 | -5.67 | ||||||||||
EBITDA | 43.67 | 91.55 | 36.48 | 35.99 | 59.13 | 70.20 | 91.64 | 112.12 | 112.13 | |||||||||
| Depreciation/Amortization | 17.35 | 10.59 | 9.29 | 12.97 | 12.15 | 12.36 | 13.44 | 27.99 | 27.99 | |||||||||
| PBIT | 26.32 | 80.96 | 27.19 | 23.02 | 46.98 | 57.84 | 78.20 | 84.13 | 84.14 | |||||||||
| Interest & Other Items | 6.47 | 4.84 | 2.53 | 1.29 | 1.42 | 0.79 | 1.11 | 4.38 | 4.38 | |||||||||
| PBT | 19.85 | 76.12 | 24.66 | 21.73 | 45.56 | 57.05 | 77.09 | 79.75 | 79.76 | |||||||||
| Taxes & Other Items | 8.65 | 12.30 | 8.45 | 5.91 | 7.47 | 14.41 | 18.91 | 18.76 | 18.77 | |||||||||
| Net Income | 11.20 | 63.82 | 16.21 | 15.82 | 38.09 | 42.64 | 58.18 | 60.99 | 60.99 | |||||||||
| EPS | 14.11 | 74.91 | 17.81 | 17.38 | 24.66 | 19.96 | 27.89 | 29.21 | 29.10 | |||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 3.50 | 4.00 | 5.50 | 5.80 | 5.50 | |||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.20 | 0.20 | 0.20 | 0.19 |
WINDLAS Company Updates
WINDLAS Stock Peers
WINDLAS Past Performance & Peer Comparison
WINDLAS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Windlas Biotech Ltd | 31.31 | 3.78 | 0.64% |
| Sun Pharmaceutical Industries Ltd | 36.94 | 5.57 | 0.95% |
| Cipla Ltd | 22.73 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 60.29 | 15.18 | 0.94% |
WINDLAS Stock Price Comparison
Compare WINDLAS with any stock or ETFCompare WINDLAS with any stock or ETF
WINDLAS
WINDLAS Holdings
WINDLAS Shareholdings
WINDLAS Promoter Holdings Trend
WINDLAS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
WINDLAS Institutional Holdings Trend
WINDLAS Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.01%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
WINDLAS Shareholding Pattern
WINDLAS Shareholding Pattern
WINDLAS Shareholding History
WINDLAS Shareholding History
Foreign Institutions
Mutual Funds Invested in WINDLAS
Mutual Funds Invested in WINDLAS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Windlas Biotech Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 4.0010% | Percentage of the fund’s portfolio invested in the stock 1.33% | Change in the portfolio weight of the stock over the last 3 months -0.48% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/47 (-9) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7127% | Percentage of the fund’s portfolio invested in the stock 0.38% | Change in the portfolio weight of the stock over the last 3 months -0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 68/130 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7239% | Percentage of the fund’s portfolio invested in the stock 1.30% | Change in the portfolio weight of the stock over the last 3 months -0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/46 (-5) |
Compare 3-month MF holding change on Screener
smallcases containing WINDLAS stock
smallcases containing WINDLAS stock
Looks like this stock is not in any smallcase yet.
WINDLAS Events
WINDLAS Events
WINDLAS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
WINDLAS Dividend Trend
No dividend trend available
WINDLAS Upcoming Dividends
WINDLAS Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 21, 2025
Final
Final | Div/Share: ₹5.80
Dividend/Share
₹5.80
Ex DateEx Date
Jul 21, 2025
WINDLAS Past Dividends
WINDLAS Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹5.50
Dividend/Share
₹5.50
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 5, 2023
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Sep 5, 2023
Cash Dividend
Ex DateEx DateSep 9, 2022
Final
Final | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Sep 9, 2022
WINDLAS Stock News & Opinions
WINDLAS Stock News & Opinions
Articles & Videos
Corporate
Windlas Biotech to convene AGM
Windlas Biotech announced that the 24th Annual General Meeting(AGM) of the company will be held on 28 July 2025.Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
Windlas Biotech Ltd Spurts 3.25%
Windlas Biotech Ltd rose 3.25% today to trade at Rs 927. The BSE Healthcare index is up 0.25% to quote at 43254.58. The index is up 2.49 % over last one month. Among the other constituents of the index, Aarti Drugs Ltd increased 1.34% and Orchid Pharma Ltd added 1.32% on the day. The BSE Healthcare index went up 17.43 % over last one year compared to the 5.26% surge in benchmark SENSEX. Windlas Biotech Ltd has lost 1.81% over last one month compared to 2.49% gain in BSE Healthcare index and 0.27% rise in the SENSEX. On the BSE, 2 shares were traded in the counter so far compared with average daily volumes of 4305 shares in the past one month. The stock hit a record high of Rs 1197 on 06 Nov 2024. The stock hit a 52-week low of Rs 656.25 on 23 Jul 2024.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Spotlight
Windlas Biotech Ltd Slips 4.88%, BSE Healthcare index Shed 1.03%
Windlas Biotech Ltd fell 4.88% today to trade at Rs 923. The BSE Healthcare index is down 1.03% to quote at 42080.34. The index is down 1.44 % over last one month. Among the other constituents of the index, Sun Pharmaceutical Industries Ltd decreased 4.08% and Indoco Remedies Ltd lost 3.58% on the day. The BSE Healthcare index went up 18.11 % over last one year compared to the 7.4% surge in benchmark SENSEX. Windlas Biotech Ltd has lost 9.89% over last one month compared to 1.44% fall in BSE Healthcare index and 1.1% rise in the SENSEX. On the BSE, 1506 shares were traded in the counter so far compared with average daily volumes of 5266 shares in the past one month. The stock hit a record high of Rs 1197 on 06 Nov 2024. The stock hit a 52-week low of Rs 552.85 on 04 Jun 2024.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Windlas Biotech consolidated net profit declines 4.18% in the March 2025 quarter
Net profit of Windlas Biotech declined 4.18% to Rs 16.28 crore in the quarter ended March 2025 as against Rs 16.99 crore during the previous quarter ended March 2024. Sales rose 18.34% to Rs 202.71 crore in the quarter ended March 2025 as against Rs 171.29 crore during the previous quarter ended March 2024. For the full year,net profit rose 4.81% to Rs 60.99 crore in the year ended March 2025 as against Rs 58.19 crore during the previous year ended March 2024. Sales rose 20.43% to Rs 759.88 crore in the year ended March 2025 as against Rs 630.96 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales202.71171.29 18 759.88630.96 20 OPM %12.6012.85 -12.3812.39 - PBDT29.1626.17 11 107.7490.54 19 PBT20.8222.63 -8 79.7677.09 3 NP16.2816.99 -4 60.9958.19 5 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Windlas Biotech recommends final dividend
Windlas Biotech announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 5.8 per equity Share (i.e. 116%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Windlas Biotech to announce Quarterly Result
Windlas Biotech will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Windlas Biotech receives affirmation in credit ratings from ICRA
Windlas Biotech has received reaffirmation in credit ratings from ICRA at ICRA A+; Stable/ ICRA A1. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Windlas Biotech consolidated net profit rises 3.18% in the December 2024 quarter
Net profit of Windlas Biotech rose 3.18% to Rs 15.58 crore in the quarter ended December 2024 as against Rs 15.10 crore during the previous quarter ended December 2023. Sales rose 20.23% to Rs 195.02 crore in the quarter ended December 2024 as against Rs 162.21 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales195.02162.21 20 OPM %12.6312.54 - PBDT27.2823.20 18 PBT20.3419.81 3 NP15.5815.10 3 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Windlas Biotech to hold board meeting
Windlas Biotech will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Windlas Biotech receives GMP certification for its new state-of-the-art injectable facility
Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 18.61%, vs industry avg of 10.15%
Over the last 5 years, market share increased from 0.13% to 0.19%
Over the last 5 years, net income has grown at a yearly rate of 30.35%, vs industry avg of 20.04%